In accordance with us, Bohler et al. demonstrated that RF and ACPA levels decreased significantly after 6 months of therapy in 143 double positive (RF + anti-CCP) established RA patients, and those reductions were closely linked to an improvement of disease activity [22]. The gene discussed is PRTN3; the disease is rheumatoid arthritis.